BPC-157 vs TB-500: Which Healing Peptide Has More Evidence?
Both are promoted for tissue repair in the biohacker world. But the two peptides work through very different mechanisms — and neither has strong human trial data.
BPC-157 and TB-500 are the two most commonly discussed "healing peptides" in the online research-chemical market. They're often stacked together in anecdotal protocols for tendon injuries, muscle strains, and surgical recovery. The marketing pitch — that they accelerate tissue repair where conventional rehab plateaus — has made them fixtures in MMA and endurance sport forums. But the actual evidence bases are different, and neither compound clears the bar of being approved for human use.
Quick comparison
| BPC-157 | TB-500 (Thymosin Beta-4) | |
|---|---|---|
| Origin | Synthetic 15-amino-acid fragment derived from human gastric juice protein (pentadecapeptide) | Synthetic fragment of Thymosin Beta-4, a 43-amino-acid protein found throughout the body |
| Primary mechanism | VEGFR2 upregulation, NO-system modulation, FAK-paxillin fibroblast activation | Actin sequestration (G-actin binding), cell migration promotion, vascular growth |
| Human trials | Phase II (ulcerative colitis, unpublished) | Phase II (dry eye, myocardial infarction — limited published data) |
| Animal evidence | Extensive — tendon, ligament, gut, skin, brain (mostly one research group) | Moderate — cardiac, corneal, cutaneous wound healing |
| Typical research route | SubQ, IP, or oral (stable in gastric acid) | SubQ or IM (oral destroys it) |
| Half-life | Not well characterized in humans | Short in serum; longer tissue residence via actin binding |
| Regulatory status | Not approved anywhere. WADA-banned (2022) | Not approved anywhere. WADA-banned (since 2011) |
BPC-157 in brief
BPC-157 ("Body Protection Compound 157") is a synthetic pentadecapeptide derived from a sequence in human gastric juice. Its research base is dominated by the Sikiric lab at the University of Zagreb, which has published hundreds of papers — almost entirely in rodents — showing acceleration of tendon, ligament, muscle, gut, and brain tissue healing. The most replicated mechanism is pro-angiogenic: BPC-157 upregulates VEGFR2 and activates the downstream Akt-eNOS axis, improving blood supply to injured tissue (🐀 animal; Hsieh et al. 2017). It also activates focal adhesion kinase (FAK) in fibroblasts, accelerating cell migration into wound sites. Despite Phase II trials in inflammatory bowel disease under the code PL 14736, detailed peer-reviewed efficacy results in humans remain unpublished. Read the full BPC-157 review.
TB-500 in brief
TB-500 is the marketing name for a synthetic fragment of Thymosin Beta-4, a naturally occurring 43-amino-acid protein present in nearly every tissue, with particularly high concentrations in platelets and wound fluid. Its primary molecular role is sequestration of G-actin (monomeric actin) — it acts as a reservoir that regulates actin polymerization, which is central to cell movement, blood-vessel sprouting, and wound closure. Animal studies show accelerated corneal re-epithelialization, post-MI cardiac repair, and cutaneous wound healing. Human trials have been conducted for dry eye (RegeneRx) and cardiac repair, but commercial development has repeatedly stalled and published efficacy data are sparse. Read the full TB-500 review.
Mechanism: different jobs, partially overlapping outcomes
Although they're often lumped together, their cellular jobs barely overlap. BPC-157 primarily drives vessel sprouting and fibroblast migration through VEGFR2 and FAK signaling — it's heavily a "grow new vessels into injury" peptide. TB-500 operates upstream of the cytoskeleton: by binding G-actin it changes how cells are able to reorganize and migrate, which matters for epithelial sheets closing a wound and for endothelial tubes forming new vessels. The overlap shows up in downstream readouts (faster closure, improved tensile strength in healed tendon in rats), but the upstream biology is quite distinct. This is why they're often stacked rather than chosen between — in theory, the two hit different parts of the wound-healing cascade.
Evidence depth: BPC-157 has more papers, TB-500 has broader sourcing
BPC-157's literature is deeper in volume — several hundred rodent studies — but heavily concentrated in one research group, which is a meaningful publication-bias and replication concern. TB-500's literature is smaller but more diverse in authorship, including work from pharma (RegeneRx) and independent cardiac and ophthalmology groups. Neither has the kind of large, independent, randomized human trial base that would support a therapeutic claim.
Side-effect profile
Both have clean acute safety in rodents. Reported human adverse effects are anecdotal only — injection-site reactions, occasional mild hypoglycemia-like symptoms with BPC-157, transient fatigue with TB-500. The unknown long-term risk for both is angiogenesis promotion in occult malignancy, because both compounds stimulate vessel formation. No human safety data exist at the multi-year scale.
Which should you choose?
Neither is FDA-approved. Both are "research use only" in the US, EU, UK, and AU. Both are WADA-banned — disqualifying for any athlete subject to drug testing. If you are going to invest effort in understanding the evidence: BPC-157 has more mechanistic studies and a clearer story for tendon/ligament applications in rats; TB-500 has a stronger theoretical case for wound/epithelial healing and slightly broader authorship. But the honest summary is that neither has published, peer-reviewed, large-scale human efficacy data. Anyone using these is making a personal risk decision outside the normal evidence-based medicine framework.
Sources
- Sikiric P. et al. "Stable Gastric Pentadecapeptide BPC 157…" Current Pharmaceutical Design, 2019. PubMed 31158953
- Hsieh M.J. et al. "Therapeutic potential of pro-angiogenic BPC 157…" J Orthop Res, 2017. PubMed 27847966
- Goldstein A.L. et al. "Thymosin β4: actin-sequestering protein moonlights to repair injured tissues." Trends Mol Med, 2005. PubMed 16154385
- Crockford D. et al. "Thymosin β4: structure, function, and biological properties supporting current and future clinical applications." Ann N Y Acad Sci, 2010. PubMed 20955325
- World Anti-Doping Agency. 2022 Prohibited List.
Related comparisons
- Ipamorelin vs CJC-1295 — both GH-release peptides
- GHK-Cu vs Minoxidil — hair growth approaches